As of 2025-05-06, the Intrinsic Value of Vertex Pharmaceuticals Inc (VRTX) is 32.32 USD. This Vertex valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 500.19 USD, the upside of Vertex Pharmaceuticals Inc is -93.50%.
The range of the Intrinsic Value is 30.33 - 33.45 USD
Based on its market price of 500.19 USD and our intrinsic valuation, Vertex Pharmaceuticals Inc (VRTX) is overvalued by 93.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (49.30) - (4.25) | (15.94) | -103.2% |
| DCF (Growth 10y) | (6.25) - (48.42) | (17.30) | -103.5% |
| DCF (EBITDA 5y) | 30.33 - 33.45 | 32.32 | -93.5% |
| DCF (EBITDA 10y) | 29.95 - 36.34 | 33.62 | -93.3% |
| Fair Value | -22.00 - -22.00 | -22.00 | -104.40% |
| P/E | (26.25) - 26.79 | (6.67) | -101.3% |
| EV/EBITDA | 27.56 - 303.28 | 162.46 | -67.5% |
| EPV | 161.95 - 206.15 | 184.05 | -63.2% |
| DDM - Stable | (21.89) - (80.52) | (51.20) | -110.2% |
| DDM - Multi | 24.85 - 72.32 | 37.14 | -92.6% |
| Market Cap (mil) | 128,588.84 |
| Beta | 0.69 |
| Outstanding shares (mil) | 257.08 |
| Enterprise Value (mil) | 122,585.74 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.50% |
| Cost of Debt | 6.65% |
| WACC | 8.49% |